Search the Community
Showing results for tags 'vasodilators'.
Found 2 results
Vasodilators and low-dose acetylsalicylic acid (ASA) are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. The present study might suggest a preventative effect on the occurrence of distinct myocardial manifestations by vasodilator therapy and low-dose ASA. PubMed, Ann rheumatologist Dis, 08/07/2019. (Also see Treatments for Systemic Scleroderma Heart Involvement) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Complex pathophysiology of pulmonary hypertension (PAH) associated with systemic sclerosis (SSc): potential unfavorable effects of vasodilators. Pre–assessment of pathophysiology of pulmonary hypertension and cautious monitoring during the treatment are necessary to achieve better outcomes in patients with SSc–PAH. Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 92 - 99. (Also see Treatments for Pulmonary Arterial Hypertension: PDE-5 Inhibitors) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.